ClinicalTrials.gg

Program

NTI164

A development code. Also written as “FEN164”.

Its studies are mostly in Autism Spectrum Disorder · Rett Syndrome · Autistic Disorder, led by Fenix Innovation Group.

Furthest: phase 3, since Nov 15, 20227 company-led studies, 2 open or runningNext primary completion: Oct 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fenix Innovation Group72 open or runningphase 3since Nov 15, 2022Apr 4, 2022Oct 1, 2028phase 3 · NCT07257978

Also a collaborator on its studies: neurotech-international-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 4, 2022First study: phase 2 study in Autism Spectrum DisorderFirst studyNCT05516407 · 18 enrolled · Australia
  2. Nov 15, 2022Phase 3 study in Autism Spectrum DisorderNCT05626959 · 54 enrolled · Australia
  3. Sep 11, 20242 phase 2 studiesNCT06621888, NCT06621043
  4. Nov 26, 2024Phase 1 study in Marijuana AbuseNCT06713447 · 12 enrolled · Australia
  5. Jul 18, 2025Phase 3 study in Rett SyndromeNCT07257978 · 40 planned · Australia
  6. Nov 17, 2025Phase 3 study in Autistic DisorderNCT07257939 · 200 planned · Australia

Ahead

  1. Oct 1, 2028Primary completion: phase 3 study in Rett SyndromeNCT07257978
  2. Jul 1, 2029Primary completion: phase 3 study in Autistic DisorderNCT07257939

TargetBeta

GCNT2 →read by rule
“NTI164 is a potently anti-inflammatory oil which has demonstrated efficacy in reducing symptoms in several paediatric neurological conditions, including RTT (Phase I/II), autism spectrum disorder (ASD), and paediatric acute-onset neuropsychicatric syndrome (PANS).”study text, by rule · the study

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07257939Autistic Disorder · Australia3Not yet recruitingJul 1, 2029200
NCT07257978Rett Syndrome · Australia3Not yet recruitingOct 1, 202840
NCT06713447Marijuana Abuse · Australia1CompletedJun 1, 202512
NCT06621888Pediatric acute-onset neuropsychiatric syndrome · Australia2CompletedDec 1, 202518
NCT06621043Rett Syndrome · Australia2CompletedDec 1, 202514
NCT05626959Autism Spectrum Disorder · Australia3CompletedMar 1, 202454
NCT05516407Autism Spectrum Disorder · Australia2CompletedSep 1, 202218

How it is read

Names in the registry

  • “NTI164”, 6 entries
  • “FEN164”, 1 entry

Codes read as this program: NTI164, FEN164.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.